This paradoxical increase suggests that while the tumor initially evades immune detection through low ANXA1 levels, under the selective pressure of immunotherapy, it may upregulate ANXA1 in immune cells to enhance its immunosuppressive environment. The gene discussed is ANXA1; the disease is neoplasm.